<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SANSERT- methysergide maleateÂ tablet, coatedÂ </strong><br>Novartis Pharmaceuticals Corporation<br></p></div>
<h1>Sansert<span class="Sup">Â®</span>
</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First">T2000-69</p>
<p>89011201</p>
<p>Â Â Â Â Â 
	Information for the physician</p>
<p></p>
<p><span class="Bold">Â Â Â Â Â 
	Sansert</span><span class="Bold"><span class="Sup">Â®</span></span></p>
<p><span class="Italics">Â Â Â Â Â 
	(methysergide maleate) tablets, USP</span></p>
<p></p>
<p><span class="Bold">Â Â Â Â Â 
	Rx only</span></p>
<p></p>
<p><span class="Bold">Â Â Â Â Â 
	Prescribing Information</span></p>
<p></p>
</div>
<div class="Warning">
<a name="section-3"></a><p></p>
<h1><span class="Bold">WARNING</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal Fibrosis</span>, Pleuropulmonary <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> and Fibrotic Thickening of Cardiac Valves May Occur in Patients Receiving Long-term Methysergide Maleate Therapy. Therefore, This Preparation Must Be Reserved for Prophylaxis in Patients Whose <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">Vascular Headaches</span> Are Frequent and/or Severe and Uncontrollable and Who Are Under Close Medical Supervision.</span><br><span class="Bold Italics">(See also WARNINGS section)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Sansert<span class="Sup">Â®</span> (methysergide maleate) is a partially synthetic compound structurally related to lysergic acid butanolamide, well-known as methylergonovine in obstetrical practice as an oxytocic agent.</p>
<p></p>
<p>Chemically, methysergide maleate is designated as ergoline-8-carboxamide, 9,10-didehydro-<span class="Italics">N</span>-[1-(hydroxymethyl)propyl]-1,6-dimethyl-, (8ÃŸ)-, (<span class="Italics">Z</span>)-2-butenedioate (1:1) (salt).</p>
<p></p>
<p>Its structural formula is:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3FAE28EE-700E-4D4F-A040-02EF01A2AEB4&amp;name=sansert-figure-02.jpg"></p>
<p></p>
<p>Methylation in the number 1 position of the ring structure enormously enhances the antagonism to serotonin which is present to a much lesser degree in the partially methylated compound (methylergonovine maleate) as well as profoundly altering other pharmacologic properties.</p>
<p></p>
<p><span class="Italics">Active Ingredient:</span> methysergide maleate, USP.</p>
<p></p>
<p><span class="Italics">Inactive Ingredients:</span> acacia, carnauba wax, colloidal silicon dioxide, FD&amp;C Blue #1, FD&amp;C Yellow #5, gelatin, lactose, malic acid, povidone, sodium benzoate, starch (corn), stearic acid, sucrose, synthetic black iron oxide, talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4"></a><p></p>
<h1><span class="Bold">ACTIONS</span></h1>
<p class="First">Sansert<span class="Sup">Â®</span> (methysergide maleate) has been shown, <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span>. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a â€œheadache substanceâ€? acting directly or indirectly to lower <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> threshold (others in this category include tyramine; polypeptides, such as bradykinin; histamine; and acetylcholine), as an intrinsic â€œmotor hormoneâ€? of the gastrointestinal tract, and as a â€œhormoneâ€? involved in connective tissue reparative processes. Suggestions have been made by investigators as to the mechanism whereby methysergide produces its clinical effects, but this has not been finally established.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1><span class="Bold">INDICATIONS</span></h1>
<p class="First">For the prevention or reduction of intensity and frequency of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span> in the following kinds of patients:</p>
<ol class="Arabic">
<li>Patients suffering from one or more severe <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span> per week.<br>
</li>
<li>Patients suffering from <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span> that are uncontrollable or so severe that preventive therapy is indicated regardless of the frequency of the attack.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the drug or to tartrazine (FD&amp;C Yellow #5) or any other components of the formulation, pregnancy, lactation, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, severe <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> or <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> of the lower limbs, pulmonary disease, collagen diseases or fibrotic processes, impaired liver or renal function, <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span>, debilitated states and serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">With long-term, uninterrupted administration, <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> or related conditions â€” pleuropulmonary <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span> with murmurs or vascular bruits have been reported. Patients must be warned to report immediately the following symptoms and to discontinue the drug: <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, numb, and painful hands and feet; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> on walking; any type of girdle, flank, or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or any associated symptomatology. Should any of these symptoms develop, methysergide should be discontinued. Continuous administration should not exceed 6 months. There must be a drug-free interval of 3-4 weeks after each 6-month course of treatment. The dosage should be reduced gradually during the last 2-3 weeks of each treatment course to avoid â€œheadache rebound.â€?</p>
<p></p>
<p>The drug is not recommended for use in children.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">All patients receiving Sansert<span class="Sup">Â®</span> (methysergide maleate) should remain under constant supervision of the physician and be examined regularly for the development of fibrotic or vascular complications. <span class="Italics">(See ADVERSE REACTIONS)</span></p>
<p></p>
<p>The manifestations of <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span>, pleuropulmonary <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, and vascular shutdown have shown a high incidence of regression once Sansert<span class="Sup">Â®</span> (methysergide maleate) is withdrawn. These facts should be borne in mind to avoid unnecessary <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>. <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">Cardiac murmurs</span>, which may indicate endocardial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, have shown varying degrees of regression, with complete disappearance in some and persistence in others.</p>
<p></p>
<p>Sansert<span class="Sup">Â®</span> (methysergide maleate) has been specifically designed for the prophylaxis of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headache</span> and has no place in the management of the acute attack.</p>
<p></p>
<p>Sansert<span class="Sup">Â®</span> (methysergide maleate) tablets contain FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible individuals. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">Information for Patients</span></h2>
<p class="First">Sansert<span class="Sup">Â®</span> (methysergide maleate) is intended for use as a preventive agent in the treatment of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span>. It should not be used for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> attacks. If, after a 3-week trial period, Sansert<span class="Sup">Â®</span> (methysergide maleate) has not been effective in decreasing the frequency or intensity of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, it is unlikely that longer administration of Sansert<span class="Sup">Â®</span> (methysergide maleate) will be beneficial.</p>
<p></p>
<p>Patients should be advised to report the following symptoms immediately and to discontinue the drug: <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, numb, and painful hands and feet; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> on walking; any type of girdle, flank, or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>; or any associated symptomatology. There must be a drug-free interval of 3-4 weeks after each 6-month course of treatment.</p>
<p></p>
<p>Sansert<span class="Sup">Â®</span> (methysergide maleate) should be taken with meals. <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> may necessitate modification of diet.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">Methysergide may reverse the analgesic activity of narcotic analgesics. Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold">Pregnancy Category X</span></h2>
<p class="First">Sansert<span class="Sup">Â®</span> (methysergide maleate) is contraindicated in pregnancy due to its oxytocic actions.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">There are no specific studies on the use of Sansert<span class="Sup">Â®</span> (methysergide maleate) in nursing mothers. Ergot alkaloids, in general, appear in mothersâ€™ milk.</p>
<p></p>
<p>Sansert<span class="Sup">Â®</span> (methysergide maleate) is a semi-synthetic compound structurally related to ergotamine, and thus it may appear in breast milk. Ergot alkaloids have been reported to cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the nursing infant and suppression of prolactin secretion and lactation in the mother.</p>
<p></p>
<p>Because of the potential for serious adverse reactions in nursing infants from Sansert<span class="Sup">Â®</span> (methysergide maleate), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.6"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">Within the recommended dose levels, the following side effects have been reported:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>
<span class="Bold">1)</span><span class="Bold">Â Â Â Â Â 
	Fibrotic Complications</span>
</h2>
<p class="First">Fibrotic changes have been observed in the retroperitoneal, pleuropulmonary, cardiac, and other tissues, either singly or, very rarely, in combination.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.1"></a><p></p>
<h3><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal Fibrosis</span></span></h3>
<p class="First">This nonspecific fibrotic process is usually confined to the retroperitoneal connective tissue above the pelvic brim and may present clinically with one or more symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, low grade <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (<span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">elevated sedimentation rate</span>), urinary obstruction (girdle or <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, elevated BUN), <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span> of the lower limbs (<span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4146311" conceptname="Leriche's syndrome">Leriche syndrome</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema of legs</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>). The single most useful diagnostic procedure in suspected cases of <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> is intravenous pyelography. Typical deviation and obstruction of one or both ureters may be observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.2"></a><p></p>
<h3><span class="Bold Italics">Pleuropulmonary Complications</span></h3>
<p class="First">A similar nonspecific fibrotic process, limited to the pleural and immediately subjacent pulmonary tissues, usually presents clinically with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, tightness and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest, pleural friction rubs, and <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>. These findings may be confirmed by chest X-ray.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.3"></a><p></p>
<h3><span class="Bold Italics">Cardiac Complications</span></h3>
<p class="First">Nonrheumatic fibrotic thickenings of the aortic root and of the aortic and mitral valves usually present clinically with <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">cardiac murmurs</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.4"></a><p></p>
<h3><span class="Bold Italics">Other Fibrotic Complications</span></h3>
<p class="First">Several cases of fibrotic plaques, simulating Peyronieâ€™s Disease have been described.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>
<span class="Bold">2)</span><span class="Bold">Â Â Â Â Â 
	Cardiovascular Complications</span>
</h2>
<p class="First">Encroachment of <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> on the aorta, inferior vena cava and their common iliac branches may result in <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span> of the lower limbs, the presenting features of which are mentioned under <span class="Italics"><span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal Fibrosis</span>.</span></p>
<p></p>
<p>Intrinsic <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> of large and small arteries, involving one or more vessels or merely a segment of a vessel, may occur at any stage of therapy. Depending on the vessel involved, this complication may present with <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, numb, painful extremities with or without <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> and diminished or absent pulses. Progression to ischemic tissue damage has rarely been reported. Prompt withdrawal of the drug at the first signs of impaired circulation is recommended <span class="Italics">(see WARNINGS)</span> to obviate such effects.</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> have also been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>
<span class="Bold">3)</span><span class="Bold">Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Symptoms</span></span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. These effects tend to appear early and can frequently be obviated by gradual introduction of the medication and by administration of the drug with meals. <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and elevation of gastric HCl have also been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>
<span class="Bold">4)</span><span class="Bold">Â Â Â Â Â 
	CNS Symptoms</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, mild <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, unworldly feelings (described variously as â€œdissociationâ€?, â€œhallucinatory experiencesâ€?, etc.). Some of these symptoms may be associated with <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span>, per se, and may, therefore, be unrelated to the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2>
<span class="Bold">5)</span><span class="Bold">Â Â Â Â Â 
	Dermatological Manifestations</span>
</h2>
<p class="First">Facial flush, <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> have rarely been reported. Increased <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> may occur, but in many instances the tendency has abated despite continued therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6"></a><p></p>
<h2>
<span class="Bold">6)</span><span class="Bold">Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>, and, more rarely, localized brawny <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may occur.</p>
<p><span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> has responded to lowered doses, salt restriction, or diuretics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.7"></a><p></p>
<h2>
<span class="Bold">7)</span><span class="Bold">Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> may be a reason to caution patients regarding their caloric intake.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8"></a><p></p>
<h2>
<span class="Bold">8)</span><span class="Bold">Â Â Â Â Â 
	Hematological Manifestations</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.9"></a><p></p>
<h2>
<span class="Bold">9)</span><span class="Bold">Â Â Â Â Â 
	Miscellaneous</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">Few cases of acute Sansert<span class="Sup">Â®</span> (methysergide maleate) <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> have been reported. The possible symptom complex is therefore not fully known. The following symptoms are based on these few case reports. <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> have been reported in a child with a dose of 20-24 mg of Sansert<span class="Sup">Â®</span> (methysergide maleate). In adults, peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, with diminished or absent pulses, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span>, mottling and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, has been observed at a dose of 200 mg. Ischemic tissue damage has not been reported in acute overdosage with Sansert<span class="Sup">Â®</span> (methysergide maleate).</p>
<p></p>
<p>Treatment consists of removal of the offending drug by induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, or gastric lavage in the case of very recent intake, repeat dose administration of activated charcoal and catharsis. There is no evidence that forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> accelerates the elimination of Sansert<span class="Sup">Â®</span> (methysergide maleate). However, I.V. fluids may be given as a general supportive measure.</p>
<p></p>
<p>Treatment of peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> should consist of warmth, but not heat, and protection of the ischemic limbs. In reported cases of Sansert<span class="Sup">Â®</span> (methysergide maleate) overdosage, the use of vasodilators has not been necessary. However, if <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> is persistent, severe, or if there is evidence of impending ischemic tissue damage, these agents may be beneficial. Careful nursing care is recommended in order to prevent tissue damage.</p>
<p></p>
<p>Up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> can often be obtained from a certified Regional Poison Control Center. Telephone numbers of certified Regional Poison Control Centers are listed in the Physiciansâ€™ Desk Reference<span class="Sup">Â®</span>.*</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Usual adult dose 4-8 mg daily. Tablets to be given with meals.</p>
<p></p>
<p><span class="Italics">Note:</span><span class="Italics">Â Â Â Â Â 
	There must be a medication-free interval of 3</span><span class="Italics">-4 weeks after every 6-month course of treatment. (See WARNINGS)</span></p>
<p></p>
<p><span class="Italics">No pediatric dosage has been established.</span></p>
<p></p>
<p>If, after a 3-week trial period, efficacy has not been demonstrated, longer administration of Sansert<span class="Sup">Â®</span> (methysergide maleate) is unlikely to be of benefit.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">Sansert</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold"> (methysergide maleate) tablets, USP</span>
</h2>
<p class="First"></p>
<p><span class="Bold">Tablets 2 mg</span></p>
<p></p>
<p>Bright yellow, coated tablets with â€œSANDOZâ€? imprinted on one side, â€œ78-58â€? imprinted on the other side, in black.</p>
<p></p>
<p>Bottle of 100â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦â€¦â€¦â€¦â€¦..NDC 0078-0058-05</p>
<p></p>
<p><span class="Bold Italics">Store and Dispense</span></p>
<p></p>
<p>Below 86Â°F (30Â°C); tight container.</p>
<p></p>
<p><a name="OLE_LINK1"></a></p>
<p><a name="OLE_LINK2"></a></p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-13"></a><p></p>
<h1><span class="Bold">ANIMAL PHARMACOLOGY AND TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2><span class="Bold">Serotonin Antagonism</span></h2>
<p class="First">Considering structure/effect relationships, it has been demonstrated that methylation of the indole nitrogen in the lysergic acid ring of the alkanolamides fundamentally alters their pharmacologic behavior and is associated with inhibition or blockade of a great variety of serotonin-induced effects:</p>
<p></p>
<table>
<thead><tr class="First Last">
<td>1.</td>
<td>Methysergide maleate is 6 times more active than methylergonovine maleate in antagonizing the effect of serotonin on the rat uterus <span class="Italics">in vitro</span>.</td>
</tr></thead>
<tbody>
<tr class="First">
<td></td>
<td align="center"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3FAE28EE-700E-4D4F-A040-02EF01A2AEB4&amp;name=sansert-figure-03.jpg"></td>
</tr>
<tr>
<td>2.</td>
<td>Greater inhibition of the serotonin-induced <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> in the ratâ€™s paw is revealed by the ED<span class="Sub">50</span> of 12.9 Âµg/kg for methysergide maleate as against 37.4 Âµg/kg for methylergonovine maleate <span class="Italics">(see following graph)</span>.</td>
</tr>
<tr>
<td></td>
<td align="center">
<img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3FAE28EE-700E-4D4F-A040-02EF01A2AEB4&amp;name=sansert-figure-04.jpg"><br>
</td>
</tr>
<tr>
<td>3.</td>
<td>The more complex effects of serotonin on the cardiovascular system are equally subject to inhibition by methysergide maleate as is evident from the subsequent record of various circulatory parameters in the dog before and after administration of 10Â Âµg/kg.</td>
</tr>
<tr class="Last">
<td></td>
<td align="center"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3FAE28EE-700E-4D4F-A040-02EF01A2AEB4&amp;name=sansert-figure-05.jpg"></td>
</tr>
</tbody>
</table>
<p></p>
<table>
<thead><tr class="First Last"><td class="Toprule" colspan="6" valign="bottom"><span class="Bold">Acute Toxicity</span></td></tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" align="center" colspan="5" valign="bottom">
<span class="Bold">LD</span><span class="Bold"><span class="Sub">50</span></span><span class="Bold"> in mg/kg</span>
</td>
</tr>
<tr>
<td class="Toprule" valign="bottom"></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold Italics Underline">Mice</span></td>
<td class="Toprule" align="center" valign="bottom"><span class="Bold Italics Underline">Rabbits</span></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold Italics Underline">Rats</span></td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Compound</span></td>
<td align="center" valign="bottom"><span class="Bold">i.v.</span></td>
<td align="center" valign="bottom"><span class="Bold">oral</span></td>
<td align="center" valign="bottom"><span class="Bold">i.v.</span></td>
<td align="center" valign="bottom"><span class="Bold">i.v.</span></td>
<td align="center" valign="bottom"><span class="Bold">oral</span></td>
</tr>
<tr>
<td class="Toprule" valign="bottom">Methysergide <br><br>maleate</td>
<td class="Toprule" align="center" valign="bottom">185</td>
<td class="Toprule" align="center" valign="bottom">581</td>
<td class="Toprule" align="center" valign="bottom">28</td>
<td class="Toprule" align="center" valign="bottom">125</td>
<td class="Toprule" align="center" valign="bottom">2100</td>
</tr>
<tr class="Last">
<td class="Toprule" valign="bottom">methylergonovine <br><br>maleate</td>
<td class="Toprule" align="center" valign="bottom">85</td>
<td class="Toprule" align="center" valign="bottom">187</td>
<td class="Toprule" align="center" valign="bottom">2.6</td>
<td class="Toprule" align="center" valign="bottom">23</td>
<td class="Toprule" align="center" valign="bottom">93</td>
</tr>
</tbody>
</table>
<p></p>
<table>
<thead><tr class="First Last"><td class="Toprule" colspan="3" valign="bottom"><span class="Bold">Chronic Toxicity</span></td></tr></thead>
<tbody>
<tr class="First"><td class="Toprule" colspan="3" valign="bottom"><span class="Bold Italics">Rats</span></td></tr>
<tr>
<td class="Toprule" align="center" valign="bottom">
<span class="Bold">Daily Oral Doses </span><span class="Bold"><br><br>mg/kg</span>
</td>
<td class="Toprule" align="center" valign="bottom">
<span class="Bold">No. of Weeks </span><span class="Bold"><br><br>Animals Tested</span>
</td>
<td class="Toprule" align="center" valign="bottom"><span class="Bold">Mortality</span></td>
</tr>
<tr>
<td class="Toprule" align="center" valign="bottom">5</td>
<td class="Toprule" align="center" valign="bottom">50</td>
<td class="Toprule" align="center" valign="bottom">4/16</td>
</tr>
<tr>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom">50</td>
<td align="center" valign="bottom">2/16</td>
</tr>
<tr>
<td align="center" valign="bottom">50</td>
<td align="center" valign="bottom">50</td>
<td align="center" valign="bottom">2/16</td>
</tr>
<tr>
<td align="center" valign="bottom">150</td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">8/30</td>
</tr>
<tr>
<td align="center" valign="bottom">450</td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">17/30</td>
</tr>
<tr class="Last">
<td align="center" valign="bottom">Control</td>
<td align="center" valign="bottom">50</td>
<td align="center" valign="bottom">1/16</td>
</tr>
</tbody>
</table>
<p></p>
<p><span class="Bold Italics">Dogs</span></p>
<p>Oral administration of 1, 2, and 5 mg/kg/day of methysergide maleate failed to produce any major signs of toxicity over a period of 6 months.</p>
<p></p>
<p>*Trademark of Medical Economics Company, Inc.</p>
<p></p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey 07936</p>
<p></p>
<p>REV: NOVEMBER 2000Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 
	   T2000-69</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SANSERTÂ 		
					</strong><br><span class="contentTableReg">methysergide maleate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0058</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>methysergide maleate</strong> (methysergide) </td>
<td class="formItem"></td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acacia</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue #1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow #5</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>malic acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch (corn)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>synthetic black iron oxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (Bright yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SANDOZ;78-58</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0058-05</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Novartis Pharmaceuticals Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>704DE278-A500-054B-E5AD-AF5251EB499A</div>
<div>Set id: 3FAE28EE-700E-4D4F-A040-02EF01A2AEB4</div>
<div>Version: 1</div>
<div>Effective Time: 20060217</div>
</div>
</div>Â <div class="DistributorName">Novartis Pharmaceuticals Corporation</div></p>
</body></html>
